Evidence map›Paper›PMID 27331807›Full record

ArticleMolecules (Basel, Switzerland)2016

Antileishmanial Activity and Structure-Activity Relationship of Triazolic Compounds Derived from the Neolignans Grandisin, Veraguensin, and Machilin G.

Eduarda C Costa, Tatiana B Cassamale, Diego B Carvalho, Lauriane S S Bosquiroli, Mariáh Ojeda, Thalita V Ximenes, Maria F C Matos, Mônica C T Kadri, Adriano C M Baroni, Carla C P Arruda

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Molecules (Basel, Switzerland) · 2022
    Article
  4. Review
  5. Article
  6. Second-generation pterocarpanquinones: synthesis and antileishmanial activity.The journal of venomous animals and toxins including tropical diseases · 2018
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eduarda C CostaLaboratório de Parasitologia Humana, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, 79090-900 Campo Grande-MS, Brazil. eduarda_c.costa@hotmail.com.
Tatiana B CassamaleLaboratório de Síntese e Química Medicinal-LASQUIM, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, 79090-900 Campo Grande-MS, Brazil. tatibortolo@gmail.com.
Diego B CarvalhoLaboratório de Síntese e Química Medicinal-LASQUIM, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, 79090-900 Campo Grande-MS, Brazil. diegob.carvalho@hotmail.com.
Lauriane S S BosquiroliLaboratório de Parasitologia Humana, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, 79090-900 Campo Grande-MS, Brazil. lauri.bosqui@gmail.com.
Mariáh OjedaLaboratório de Biologia Molecular e Culturas Celulares, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, 79090-900 Campo Grande-MS, Brazil. mariahojeda@live.com.
Thalita V XimenesLaboratório de Biofisiofarmacologia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, 79090-900 Campo Grande-MS, Brazil. thalitario@hotmail.com.
Maria F C MatosLaboratório de Biologia Molecular e Culturas Celulares, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, 79090-900 Campo Grande-MS, Brazil. matosmfc@gmail.com.
Mônica C T KadriLaboratório de Biofisiofarmacologia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, 79090-900 Campo Grande-MS, Brazil. monica.kadri@ufms.br.
Adriano C M BaroniLaboratório de Síntese e Química Medicinal-LASQUIM, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, 79090-900 Campo Grande-MS, Brazil. adrianobaroni@hotmail.com.
Carla C P ArrudaLaboratório de Parasitologia Humana, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, 79090-900 Campo Grande-MS, Brazil. carla.arruda@ufms.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sixteen 1,4-diaryl-1,2,3-triazole compounds 4-19 derived from the tetrahydrofuran neolignans veraguensin 1, grandisin 2, and machilin G 3 were tested against Leishmania (Leishmania) amazonensis intracellular amastigotes. Triazole compounds 4-19 were synthetized via Click Chemistry strategy by 1,3-dipolar cycloaddition between terminal acetylenes and aryl azides containing methoxy and methylenedioxy groups as substituents. Our results suggest that most derivatives were active against intracellular amastigotes, with IC50 values ranging from 4.4 to 32.7 µM. The index of molecular hydrophobicity (ClogP) ranged from 2.8 to 3.4, reflecting a lipophilicity/hydrosolubility rate suitable for transport across membranes, which may have resulted in the potent antileishmanial activity observed. Regarding structure-activity relationship (SAR), compounds 14 and 19, containing a trimethoxy group, were the most active (IC50 values of 5.6 and 4.4 µM, respectively), with low cytotoxicity on mammalian cells (SI = 14.1 and 10.6). These compounds induced nitric oxide production by the host macrophage cells, which could be suggested as the mechanism involved in the intracellular killing of parasites. These results would be useful for the planning of new derivatives with higher antileishmanial activities.

Indexed as

AnimalsAntiprotozoal AgentsFuransHumansLeishmaniaLeishmaniasisLignansMacrophagesNitric OxideStructure-Activity RelationshipAntiprotozoal AgentsFuransgalgravingrandisinLignansNitric Oxidetetrahydrofuranbiological activitycytotoxicityneglected diseasesneolignan derivativessynthetic compounds

Identifiers

PMID27331807
PMCPMC6273954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.